Select Publications
Journal articles
, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0
, 2023, 'Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.', Journal of Clinical Oncology, 41, pp. 3101 - 3101, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3101
, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594
, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.4093
, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.1540
, 2023, 'Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.', Journal of Clinical Oncology, 41, pp. 10578 - 10578, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10578
, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.5526
, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3127
, 2023, 'Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare', American Journal of Human Genetics, 110, pp. 419 - 426, http://dx.doi.org/10.1016/j.ajhg.2023.01.018
, 2023, 'Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab', Molecular Oncology, 17, pp. 298 - 311, http://dx.doi.org/10.1002/1878-0261.13349
, 2023, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', Science, 379, pp. 253 - 260, http://dx.doi.org/10.1126/science.abj4784
, 2022, 'Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients with Cancer: A Narrative Review', JAMA Oncology, 8, pp. 1830 - 1839, http://dx.doi.org/10.1001/jamaoncol.2022.4457
, 2022, 'Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers', Asia Pacific Journal of Clinical Oncology, 18, pp. 660 - 668, http://dx.doi.org/10.1111/ajco.13745
, 2022, 'Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-30496-0
, 2022, 'Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments', Cancer Treatment Reviews, 110, http://dx.doi.org/10.1016/j.ctrv.2022.102455
, 2022, 'Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness?', Healthcare Switzerland, 10, http://dx.doi.org/10.3390/healthcare10102086
, 2022, 'Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study', Supportive Care in Cancer, 30, pp. 8201 - 8210, http://dx.doi.org/10.1007/s00520-022-07272-3
, 2022, 'Using whole-genome sequencing to characterize clinically significant blood groups among healthy older Australians', Blood Advances, 6, pp. 4593 - 4604, http://dx.doi.org/10.1182/bloodadvances.2022007505
, 2022, 'Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting', European Journal of Human Genetics, 30, pp. 930 - 937, http://dx.doi.org/10.1038/s41431-022-01069-y
, 2022, 'Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients', Patient Education and Counseling, 105, pp. 2206 - 2216, http://dx.doi.org/10.1016/j.pec.2022.01.011
, 2022, 'Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling', International Journal of Technology Assessment in Health Care, 38, http://dx.doi.org/10.1017/S026646232200040X
, 2022, 'Psychological predictors of cancer patients' and their relatives’ attitudes towards the return of genomic sequencing results', European Journal of Medical Genetics, 65, http://dx.doi.org/10.1016/j.ejmg.2022.104516
, 2022, 'Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions', Public Health Genomics, 25, pp. 70 - 79, http://dx.doi.org/10.1159/000520000
, 2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, 14, pp. emmm202114608, http://dx.doi.org/10.15252/emmm.202114608
, 2022, 'Population DNA screening for medically actionable disease risk in adults', Medical Journal of Australia, 216, pp. 278 - 280, http://dx.doi.org/10.5694/mja2.51454
, 2022, 'Delivering precision oncology to patients with cancer', Nature Medicine, 28, pp. 658 - 665, http://dx.doi.org/10.1038/s41591-022-01717-2
, 2022, 'Cancer patient knowledge about and behavioral intentions after germline genome sequencing', Patient Education and Counseling, 105, pp. 707 - 718, http://dx.doi.org/10.1016/j.pec.2021.07.004
, 2022, 'Psychological predictors of advanced cancer patients’ preferences for return of results from comprehensive tumor genomic profiling', American Journal of Medical Genetics Part A, 188, pp. 725 - 734, http://dx.doi.org/10.1002/ajmg.a.62563
, 2022, 'Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients', Patient Education and Counseling, 105, pp. 452 - 459, http://dx.doi.org/10.1016/j.pec.2021.05.018
, 2022, 'Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer', Genes Chromosomes and Cancer, 61, pp. 81 - 93, http://dx.doi.org/10.1002/gcc.23006
, 2022, 'Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study', Journal of Genetic Counseling, 31, pp. 96 - 108, http://dx.doi.org/10.1002/jgc4.1455
, 2022, 'Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion', JCO PRECISION ONCOLOGY, 6, http://dx.doi.org/10.1200/PO.22.00263
, 2022, 'Psychological Outcomes in Advanced Cancer Patients After Receiving Genomic Tumor Profiling Results', Health Psychology, 41, pp. 396 - 408, http://dx.doi.org/10.1037/hea0001181
, 2022, '1487MO A pan-sarcoma investigation of genetic alterations associated with high telomeric content', Annals of Oncology, 33, pp. S1226 - S1227, http://dx.doi.org/10.1016/j.annonc.2022.07.1590
, 2022, 'Questioning the ethics of evidence-based practice for Indigenous health and social settings in Australia', BMJ GLOBAL HEALTH, 7, http://dx.doi.org/10.1136/bmjgh-2022-009167
, 2021, 'ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data', Genome Medicine, 13, pp. 32, http://dx.doi.org/10.1186/s13073-021-00841-x
, 2021, 'Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology', Npj Precision Oncology, 5, pp. 58, http://dx.doi.org/10.1038/s41698-021-00194-z
, 2021, 'Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions', Genome Biology, 22, pp. 109, http://dx.doi.org/10.1186/s13059-021-02315-0
, 2021, 'Fear of cancer recurrence in patients undergoing germline genome sequencing', Supportive Care in Cancer, 29, pp. 7289 - 7297, http://dx.doi.org/10.1007/s00520-021-06311-9
, 2021, 'Germline PALB2 variants and PARP inhibitors in endometrial cancer', Jnccn Journal of the National Comprehensive Cancer Network, 19, pp. 1212 - 1217, http://dx.doi.org/10.6004/jnccn.2021.7067
, 2021, 'Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling', Psycho Oncology, 30, pp. 1920 - 1929, http://dx.doi.org/10.1002/pon.5764
, 2021, 'Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer', Leukemia, 35, pp. 3245 - 3256, http://dx.doi.org/10.1038/s41375-021-01246-w
, 2021, 'The experiences and needs of australian medical oncologists in integrating comprehensive genomic profiling into clinical care: A nation-wide survey', Oncotarget, 12, pp. 2169 - 2176, http://dx.doi.org/10.18632/ONCOTARGET.28076
, 2021, 'Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities', Cancer, 127, pp. 2934 - 2942, http://dx.doi.org/10.1002/cncr.33618
, 2021, 'Does undertaking genome sequencing prompt actual and planned lifestyle-related behavior change in cancer patients and survivors? A qualitative study', Journal of Psychosocial Oncology Research and Practice, 3, pp. E059, http://dx.doi.org/10.1097/OR9.0000000000000059
, 2021, 'Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: ‘Another piece of the pie’', Journal of Genetic Counseling, 30, pp. 849 - 860, http://dx.doi.org/10.1002/jgc4.1384
, 2021, 'Family communication about genomic sequencing: A qualitative study with cancer patients and relatives', Patient Education and Counseling, 104, pp. 944 - 952, http://dx.doi.org/10.1016/j.pec.2020.10.022
, 2021, 'PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma', Cancer Reports, 4, http://dx.doi.org/10.1002/cnr2.1327
, 2021, 'Germline RET variants underlie a subset of paediatric osteosarcoma', Journal of Medical Genetics, 58, pp. 20 - 24, http://dx.doi.org/10.1136/jmedgenet-2019-106734
, 2021, 'Novel RET fusion RET-SEPTIN9 predicts response to selective RET inhibition with selpercatinib in malignant pheochromocytoma', JCO Precision Oncology, 5, pp. 1160 - 1165, http://dx.doi.org/10.1200/PO.21.00127